---
description: Modular vendor models look flexible early and cost programs months at every handoff. What an integrated CDMO strategy changes for advanced therapy developers, and what it does not.
title: Integrated vs. Modular CDMO Strategy for Advanced Therapies
---

[![Artis BioSolutions](https://blog.artisbiosolutions.com/hubfs/logo_artis_landscape%202.svg)](https://artisbiosolutions.com)

- [Home](https://artisbiosolutions.com)
- [Contact](https://artisbiosolutions.com/contact)

#### [← Back to Blog](https://blog.artisbiosolutions.com)

# Integrated vs. Modular CDMO Strategy for Advanced Therapies

###### Artis BioSolutions

November 18, 2026

The advanced therapy sector has historically operated within a highly fragmented manufacturing ecosystem. As cell and gene therapy developers transition complex programs into the clinic, they frequently navigate an uncoordinated network of vendors: sourcing starting materials from one supplier, executing process development with another, and transferring the finalized protocol to a third partner for cGMP production. Across sponsor programs, we routinely observe that this fragmented paradigm introduces significant operational risk, structural delays, and compounding data loss. Advanced therapy developers must evaluate the strategic trade-offs between a traditional modular vendor model and a fully integrated contract development and manufacturing strategy.

## The vulnerabilities of modular handoffs

A modular manufacturing strategy, where specific unit operations or phases of development are outsourced to niche vendors, can appear advantageous during early-phase research. It allows sponsors to select specialized providers for independent tasks, such as plasmid synthesis, analytical assay design, or fill-and-finish services. This approach offers localized flexibility, but it creates structural friction during technology transfer.

Every transition requires a formal handoff of documentation, analytical methods, and material handling protocols. In our experience, these handoffs are precisely where advanced therapy programs lose momentum. Minor discrepancies in instrumentation, differences in software versions, or varying interpretations of raw material specifications can stall a program for months. Furthermore, when a manufacturing deviation occurs in a modular model, determining the root cause becomes an administrative challenge. The viral vector manufacturer may point to plasmid quality variations, while the plasmid supplier points to downstream processing parameters, leaving the sponsor to manage the operational and financial fallout.

## The strategic advantage of upstream and downstream integration

An integrated CDMO strategy eliminates this operational friction by consolidating the entire development and manufacturing lifecycle within a single corporate and quality architecture. At Artis BioSolutions, we built our platform to address the exact points of failure we watched sponsors suffer through in fragmented supply chains. By combining our cell-free synthetic DNA manufacturing with our downstream clinical scale-up capabilities, we provide an unbroken operational thread.

This integration yields immediate technical advantages, particularly in the production of viral vectors and advanced cell therapies. When our synthetic DNA production teams work in direct alignment with our AAV and lentiviral vector suites, the starting material format can be optimized specifically for the downstream transfection process. Our enzymatic, plasmid-free process replaces legacy bacterial fermentation, delivering highly homogenous starting material in a fraction of the traditional lead time. Because this starting material is engineered in house to eliminate bacterial endotoxins and sequence instability, the downstream team works from a cleaner, more predictable input.

## Maintaining process and data continuity

True integration goes beyond housing equipment under one roof; it requires absolute harmonization of data and quality systems. Our development laboratories run the same automated platforms, sensor configurations, and analytical instruments as our cGMP cleanroom suites. This environmental mirroring removes the traditional guesswork that typically derails classical tech transfers.

When a program moves from process development to clinical manufacturing, the physical parameters are already understood. The data accumulated during early engineering runs flows into the Chemistry, Manufacturing, and Controls data package required for Investigational New Drug submissions. This continuous data thread provides regulatory reviewers with transparent evidence of process understanding and control, reducing the likelihood of unexpected clinical holds or late-stage comparability requests.

## Aligning strategy with clinical realities

For advanced therapy sponsors, speed to market and capital efficiency are critical. While a modular approach may distribute initial costs across multiple independent vendors, the hidden expenses of re-validation studies, extended timelines, and project management oversight can quickly erase those perceived savings.

A fully integrated partnership model provides a de-risked pathway through clinical translation. By aligning synthetic DNA production, analytical qualification, and cGMP manufacturing under a unified quality framework across our operations in the United States and the European Union, Artis BioSolutions enables sponsors to eliminate external handoffs, reduce regulatory friction through comprehensive data traceability, and accelerate the delivery of transformative medicines to patients.

[Learn More](https://www.hubspot.com/)

Share this post

<http://www.linkedin.com/shareArticle?mini=true&url=https://blog.artisbiosolutions.com/integrated-vs.-modular-cdmo-strategy-for-advanced-therapies> [mailto:?subject=Check%20out%20this%20post&body=https://blog.artisbiosolutions.com/integrated-vs.-modular-cdmo-strategy-for-advanced-therapies](mailto:?subject=Check%20out%20this%20post&body=https://blog.artisbiosolutions.com/integrated-vs.-modular-cdmo-strategy-for-advanced-therapies)

## Keep reading

#### [SERVICES](https://artisbiosolutions.com/services)

- [Process Development](https://artisbiosolutions.com/services/process-development)
- [Analytical Development](https://artisbiosolutions.com/services/analytical-development)
- [GMP Manufacturing](https://artisbiosolutions.com/services/gmp-manufacturing)
- [CMC Strategy](https://artisbiosolutions.com/services/cmc-strategy)

[![LinkedIn](https://blog.artisbiosolutions.com/hubfs/LinkedIn.svg)](https://www.linkedin.com/company/artisbiosolutions/)

#### [SYNTHETIC DNA](https://artisbiosolutions.com/synthetic-dna)

- [Why Cell-Free DNA](https://artisbiosolutions.com/synthetic-dna/why-cell-free-dna)
- [oDNA Platform](https://artisbiosolutions.com/synthetic-dna/odna-platform)

#### [THERAPEUTIC MODALITIES](https://artisbiosolutions.com/therapeutic-modalities)

- [Cell Therapy](https://artisbiosolutions.com/therapeutic-modalities/cell-therapy)
- [Viral Vectors](https://artisbiosolutions.com/therapeutic-modalities/viral-vectors)
- [Non-Viral Delivery](https://artisbiosolutions.com/therapeutic-modalities/non-viral-delivery)

#### [COMPANY](https://artisbiosolutions.com/company/about)

- [About](https://artisbiosolutions.com/company/about)
- [Facilities](https://artisbiosolutions.com/company/facilities)
- [Partnering](https://artisbiosolutions.com/company/partnering)
- [Resources](https://artisbiosolutions.com/company/resources)
- [Contact](https://artisbiosolutions.com/contact)

[![Artis BioSolutions](https://blog.artisbiosolutions.com/hubfs/logo_artis_landscape%202.svg)](https://artisbiosolutions.com)

© 2026 Artis BioSolutions. All rights reserved.

[Privacy Policy](https://artisbiosolutions.com/privacy-policy) [Cookies Settings](https://artisbiosolutions.com/cookies)

```json
{
  "@context" : "https://schema.org",
  "@type" : "BlogPosting",
  "author" : {
    "@type" : "Person",
    "name" : "Artis BioSolutions",
    "url" : "https://blog.artisbiosolutions.com/author/artis-biosolutions"
  },
  "dateModified" : "2026-11-18T15:00:00.584Z",
  "datePublished" : "2026-11-18T15:00:00.000Z",
  "headline" : "Integrated vs. Modular CDMO Strategy for Advanced Therapies",
  "mainEntityOfPage" : {
    "@id" : "https://blog.artisbiosolutions.com/integrated-vs.-modular-cdmo-strategy-for-advanced-therapies",
    "@type" : "WebPage"
  },
  "publisher" : {
    "@type" : "Organization",
    "logo" : {
      "@type" : "ImageObject",
      "url" : "https://blog.artisbiosolutions.com/hubfs/logo_artis_landscape%20(7).png"
    },
    "name" : "Artis BioSolutions"
  }
}
```